Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Beta Bionics, Inc.

BBNXNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:08 PM ESTFiling CIK 1674632Accession 0000919574-26-008109
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Beta Bionics, Inc.
Company CIK
0001674632
Street
11 HUGHES
City
IRVINE
State / country code
CA
Postal code
92618

Statement details

Amendment number
1
Security class
Common Stock, par value $0.0001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Point72 Asset Management, L.P.
Citizenship / organization
DE
Reporting person type
PN
Group designation
b
Aggregate amount owned
967,144.00
Percent of class
1.8
Sole voting power
0.00
Shared voting power
967,144.00
Sole dispositive power
0.00
Shared dispositive power
967,144.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Point72 Capital Advisors, Inc.
Citizenship / organization
DE
Reporting person type
CO
Group designation
b
Aggregate amount owned
967,144.00
Percent of class
1.8
Sole voting power
0.00
Shared voting power
967,144.00
Sole dispositive power
0.00
Shared dispositive power
967,144.00
Aggregate excludes certain shares
N

Reporting person 3

Name
Steven A. Cohen
Citizenship / organization
X1
Reporting person type
IN
Group designation
b
Aggregate amount owned
967,144.00
Percent of class
1.8
Sole voting power
0.00
Shared voting power
967,144.00
Sole dispositive power
0.00
Shared dispositive power
967,144.00
Aggregate excludes certain shares
N

Item 1

Issuer

Beta Bionics, Inc.

Principal executive office address

11 Hughes, Irvine, California 92618

Item 2

Citizenship

Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.

Filing person

This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Beta Bionics, Inc. (the "Issuer") held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Each of Cubist Systematic Strategies, LLC and Point72 Europe (London) LLP are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Shares reported herein.

Principal business or residence address

The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

Item 3

Not applicable indication

Y

Item 4

Percent of class

1.8%

Amount beneficially owned

The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 53,946,211 Shares outstanding, which is the sum of: (i) 44,989,688 Shares outstanding as of July 27, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission (the "SEC") on July 29, 2026; (ii) 7,652,175 Shares issued in the offering described in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the SEC on September 17, 2026; and (iii) 1,304,348 Shares issued pursuant to the full exercise of the underwriters' option to purchase additional Shares, as disclosed in the press release issued by the Issuer on September 17, 2026.

Sole voting power

The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.

Shared voting power

The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.

Sole dispositive power

The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.

Shared dispositive power

The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

See Item 2(a).

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
Point72 Asset Management, L.P.
Signed
/s/ Jason M. Colombo
Title
Jason M. Colombo, Authorized Person
Date
11/16/2026

Signature 2

Reporting person
Point72 Capital Advisors, Inc.
Signed
/s/ Jason M. Colombo
Title
Jason M. Colombo, Authorized Person
Date
11/16/2026

Signature 3

Reporting person
Steven A. Cohen
Signed
/s/ Jason M. Colombo
Title
Jason M. Colombo, Authorized Person
Date
11/16/2026

Company context

We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control an

Current securities

Recent company filings

  1. 10-Q filingOct 27, 2026
  2. Results of Operations and Financial ConditionOct 27, 2026
  3. SCHEDULE 13G - filed by PRICE T ROWE ASSOCIATES INC /MD/ regarding Beta Bionics, Inc.Oct 7, 2026
  4. 144 filingSep 22, 2026
  5. 4 filingSep 17, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.